Last reviewed · How we verify
Anti-BCMA CAR T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Anti-BCMA CAR T cells (Anti-BCMA CAR T cells) — Allife Medical Science and Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-BCMA CAR T cells TARGET | Anti-BCMA CAR T cells | Allife Medical Science and Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-BCMA CAR T cells CI watch — RSS
- Anti-BCMA CAR T cells CI watch — Atom
- Anti-BCMA CAR T cells CI watch — JSON
- Anti-BCMA CAR T cells alone — RSS
Cite this brief
Drug Landscape (2026). Anti-BCMA CAR T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-bcma-car-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab